Trastuzumab Deruxtecan in Patients With HER2-Positive Advanced Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
Lancet Oncol 2024 Aug 05;[EPub Ahead of Print], K Raghav, S Siena, A Takashima, T Kato, M Van den Eynde, F Pietrantonio, Y Komatsu, H Kawakami, M Peeters, T Andre, S Lonardi, K Yamaguchi, J Tie, CG Castro, HC Hsu, JH Strickler, TY Kim, Y Cha, D Barrios, Q Yan, T Kamio, K Kobayashi, A Boran, M Koga, JD Allard, T YoshinoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.